Piper Sandler analyst David Westenberg raised the firm’s price target on Labcorp (LH) to $300 from $270 following quarterly results. The firm keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp collaborates with PathAI to deploy FDA-cleared pathology platform
- Labcorp price target raised to $326 from $313 at Baird
- Labcorp price target raised to $330 from $319 at JPMorgan
- Labcorp: Short-Term Headwinds but Strengthening 2026 Outlook Supports Buy Rating
- Labcorp Earnings Call Highlights Growth, Investment, Risks